NEW YORK, March 15 (Reuters) - Shares of Medtronic Inc rose 3.6 percent to $45.50 in premarket trading on Monday after researchers said that the company's atrial fibrillation system was nearly 10 times better at eliminating a heart rhythm disorder than conventional anti-arrhythmic drugs.
For details, see
(Reporting by Ryan Vlastelica, Editing by Chizu Nomiyama) Keywords: MARKETS STOCKS BEFORETHEBELL (ryan.vlastelica@thomsonreuters.com; Tel: +1 646-223-6014; Reuters Messaging: ryan.vlastelica@reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
For details, see
(Reporting by Ryan Vlastelica, Editing by Chizu Nomiyama) Keywords: MARKETS STOCKS BEFORETHEBELL (ryan.vlastelica@thomsonreuters.com; Tel: +1 646-223-6014; Reuters Messaging: ryan.vlastelica@reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
